Pharmacosmos

Pharmacosmos is considered a world leading authority in treatment of iron deficiency anaemia.

Pharmacosmos A/S
Private
IndustryPharmaceuticals, Healthcare
Founded1965
HeadquartersHolbaek, Denmark
Key people
Lars Christensen (President and CEO), Jacob Tolstrup (Chairman of the Board)
ProductsMonofer, Cosmofer, Uniferon, Pharmacosmos Dextrans
Number of employees
280 (2020)
Websitewww.pharmacosmos.com/ 

The privately owned specialty pharmaceutical company, established in 1965 in Holbaek outside Copenhagen, Denmark, markets its human and veterinary medicines in a large number of markets throughout the world. The company's brands are MonoFer, CosmoFer and Uniferon.

Pharmacosmos maintains an intensive research and development programme targeting iron deficiency therapies and improvement of treatment options. The company is also a world leader in manufacturing of carbohydrate polymers and iron carbohydrate complexes, an expert in dextran fractionation techniques, and supplies clinical grade dextran fractions complying with the major pharmacopoeias (EP, USP and JP).

Pharmacosmos has its headquarters in Holbaek, Denmark and affiliates in the US, UK, Ireland, Germany, Sweden and Norway

Company profile

Pharmacosmos was founded in Denmark in 1965 by Henry Marinus Christensen, M.D., Ph.D.

Operations

Pharmacosmos' corporate headquarters, manufacturing facilities and research laboratories are located in Holbaek, Denmark (Scandinavia). The company has its own marketing, sales and services operations in Denmark and US, UK, Ireland, Germany, Sweden and Norway.[1] In other geographies, the company partners with other pharmaceutical companies responsible for local marketing, sales and distribution of its pharmaceuticals brands. The company does not disclose its revenues.

Manufacturing facilities

Pharmacosmos' manufacturing facility is approved according to current Good Manufacturing Practice (GMP) by the European Medicines Agency (EMA) and by the U.S. Food and Drug Administration (FDA).

Research and development

The company has an ongoing clinical development program aimed at improving treatment options for patients suffering from iron deficiency anemia. In 2010, Pharmacosmos' clinical program included three international clinical studies focused on treatment of iron deficiency anemic patients within nephrology, gastroenterology and hematology/oncology.[2][3][4]

Products

Monofer

Monofer is a treatment for iron deficiency anemia. The generic name of Monofer is iron isomaltoside 1000, developed by Pharmacosmos. Monofer was approved in December 2009 in 22 European countries for treatment of iron deficiency anemia in patients with varying underlying conditions.[5][6] Monofer is approved with a wide dose range and no test dose requirement, allowing iron repletion in a single IV dose if a Total Dose Infusion is given in certain clinical situations.[7] This has to be given in a hospital due to increased risks of reaction. If the patient requires a dose over 20 mg/kg of idealised body weight a second dose has to be given after waiting a week.[8]

Cosmofer

Cosmofer is a treatment for iron deficiency anemia. The generic name of Cosmofer is low molecular weight iron dextran. Cosmofer was approved in 2001 and is available in more than 45 countries worldwide. It has a lower incidence of dextran-induced analphylaxis than older dextran-based products, although still requires a test dose.[9]

Uniferon

Uniferon is for the treatment and prevention of iron deficiency anemia in animals. The generic name for Uniferon is iron dextran. Its approved by health authorities in Europe, Asia and in the U.S. by Food and Drug Administration (FDA).

Dextrans

Pharmacosmos is one of the world leaders within production and fractionation of carbohydrates in particular Dextran. Pharmacosmos has a unique water-based technology and production platform for polymer fractioning and derivative synthesis.

See also

References
  1. "Pharmacosmos establishes UK subsidiary after merger with Vitaline Pharmaceuticals UK Ltd". Pharmacosmos.com. Retrieved 2010-08-01.
  2. ClinicalTrials.gov identifier no. NCT01102413
  3. ClinicalTrials.gov identifier no. NCT01017614
  4. ClinicalTrials.gov identifier no. NCT01145638
  5. Sinha, S.; Kalra, P. (2010). "Treating the Anemic Oncology Patient with Intravenous Iron: Why, When, and How?" (PDF). European Journal of Clinical & Medical Oncology. San Lucas Medical. 2 (1): 113.
  6. "Pharmacosmos' Monofer Receives Approval for Treatment of Iron Deficiency Anemia". Pharmacosmos.com. Retrieved 2010-02-20.
  7. "Medscape Medical: New Iron Preparation Allows Iron Repletion in Single IV Dose". Medscape.com. Retrieved 2010-08-18.
  8. http://www.medicines.org.uk/emc/medicine/23669#POSOLOGY
  9. http://www.medicines.org.uk/emc/medicine/14139/SPC/cosmofer#POSOLOGY
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.